Learning Tracks

In this session, industry panelists will discuss how they are working across multiple, global health authorities to address Nitrosamine considerations and provide their perspective on how it is preparing for Nitrosamines limits. Industry will provide examples of inconsistencies across different global authorities, the challenges this creates, and outline recommendations on how Industry can work with the FDA (and other HAs) to address these challenges, so patients continue to have access to needed products.